Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 15/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.34 |
| ▸ | RXRA | P19793 | 2/20 | 0.34 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL782219 | 0.94 | ABCG2 (0.37) | ABCG2GABRG2GABRB3GABRA5NR1H2 | |
| SCHEMBL783272 | 0.92 | ABCG2 (0.35) | ABCG2GABRG2GABRB3GABRA5NR1H2 | |
| SCHEMBL782312 | 0.88 | CCNB2 (0.40) | GABRG2GABRB3GABRA5NR1H2NR1H3 | |
| SCHEMBL783271 | 0.88 | ABCG2 (0.34) | ABCG2NR1H2NR1H3 | |
| SCHEMBL802738 | 0.86 | MEN1 (0.33) | — | |
| SCHEMBL782089 | 0.85 | MEN1 (0.33) | — | |
| SCHEMBL802996 | 0.85 | MEN1 (0.33) | — | |
| SCHEMBL782572 | 0.84 | NR1H2 (0.36) | GABRG2GABRB3GABRA5NR1H2NR1H3 | |
| SCHEMBL802490 | 0.84 | MEN1 (0.33) | — | |
| SCHEMBL802689 | 0.84 | MEN1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9537105-B2 | Materials for organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2017-01-03 | — | — | US | disclosed |
| US-20150318478-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2015-11-05 | — | — | US | disclosed |
| US-20150318478-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2015-11-05 | — | — | US | disclosed |
| US-9126970-B2 | Materials for organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2015-09-08 | — | — | US | disclosed |
| US-9126970-B2 | Materials for organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2015-09-08 | — | — | US | disclosed |
| US-20120068170-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120068170-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| WO-2010136109-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150318478-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | SLCO2B1, SLCO1B3, SLCO4C1 | ABCG2 546/4885GABRG2 3049/4885GABRB3 1219/4885 |
| US-20120068170-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | SLCO2B1, SLCO1B3, SLCO4C1 | ABCG2 546/4885GABRG2 3049/4885GABRB3 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.